Diabetes epidemiology and management最新文献

{"title":"Utility of glucose, lipid and kidney function trajectory measures for incident cardiovascular disease risk prediction for people living with type 2 diabetes: A case-study using Danish registry data","authors":"Peter P Harms,&nbsp;Omar Silverman-Retana,&nbsp;Jonas Schaarup,&nbsp;Marieke T Blom,&nbsp;Anders A Isaksen,&nbsp;Daniel R Witte","doi":"10.1016/j.deman.2026.100331","DOIUrl":"10.1016/j.deman.2026.100331","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular disease (CVD) is an important complication of type 2 diabetes (T2D). Current CVD-prediction models use single baseline measurements and achieve moderate performance (C-indices ≈0.7). Repeated measurements available in modern healthcare registries may provide incremental predictive value. In this case study, we investigated whether HbA1c, LDL-cholesterol and eGFR trajectory measures might improve incident CVD-risk prediction.</div></div><div><h3>Methods</h3><div>We studied 83,326 people with T2D from Danish nationwide registers without CVD-history at baseline (1st January 2015), who had ≥2 HbA1c, LDL-cholesterol and eGFR measurements between 2012–2014; their last measurement defined baseline. For each risk-factor we derived three paired trajectory measures across 2012–2014: mean &amp; SD, median &amp; IQR, and intercept &amp; slope from growth models. A reference Cox-regression model for CVD-events (ICD-10 codes, until 31st December 2020) included baseline age, sex, age-at-T2D-onset, HbA1c, LDL-cholesterol, HDL-cholesterol, eGFR, and medication use. Trajectory measures were added sequentially and jointly using an offset-procedure, computing hazard ratios (HRs), C-indices and continuous net reclassification index (NRI) with 95% CIs.</div></div><div><h3>Results</h3><div>Mean age was 65 (SD±12), and 48% were female. Over median 6 years 11,280 (13.5%) people experienced a CVD-event. Accounting for the reference model, trajectory measures of dispersion and change were associated with CVD-events (HRs ≈ 1.1 for HbA1c and eGFR; &gt;1.4 for LDL-cholesterol), centrality measures were not. Adding trajectory measures produced minimal discrimination gains (C-index Δ +0.001-+0.003) but modest NRI improvements (+3-+9%).</div></div><div><h3>Conclusions</h3><div>Within-person dispersion or change measures for HbA1c, eGFR, and especially LDL-cholesterol, obtained from routine data, might moderately enhance incident CVD-risk prediction in people with T2D.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100331"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148730309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited health literacy and medication knowledge in type 2 diabetes patients from a socially deprived area of Greater Paris (Seine-Saint-Denis)","authors":"Omar Nouhou Koutcha,&nbsp;Imen Rezgani,&nbsp;Jinene EL Fahid,&nbsp;Emmanuel Cosson,&nbsp;Hélène Bihan","doi":"10.1016/j.deman.2026.100327","DOIUrl":"10.1016/j.deman.2026.100327","url":null,"abstract":"<div><h3>Introduction</h3><div>Health literacy (HL) influences patients' understanding of their disease and treatment and may affect diabetes self-management. We evaluated the prevalence of HL among patients with type 2 diabetes living in a socially deprived area of Greater Paris and examined its association with medication knowledge.</div></div><div><h3>Material and methods</h3><div>We conducted a non-interventional cross-sectional study of adults with type 2 diabetes. HL was assessed using the HLS-EU-Q16 questionnaire. Knowledge of medication dosage and medication purpose was assessed for each prescribed medication.</div></div><div><h3>Results</h3><div>The 103 participants included comprised 53 men and 50 women; mean age was 54 ± 8 years, mean duration of diabetes was 14.2 ± 8.5 years, and the majority were immigrants (68.9%). Most participants had a low or intermediate educational level (78.6%) and a low socioeconomic status (89.3%; ESeC classification). The mean HL score was 8.95 (range 0–16). Forty-eight participants (46.6%) had inadequate HL, 37 (35.9%) had problematic HL and 18 (17.5%) had adequate HL. Participants with limited HL were less likely to have French as their mother language and more likely to have an immigrant background, a lower educational level, a lower socioeconomic status, require additional information about their diabetes treatment, and receive home nursing support. Mean medication-dosage and medication-purpose knowledge scores were 83% and 67%, respectively. Higher HL score remained independently associated with better medication-purpose knowledge after adjustment for major sociodemographic and clinical factors.</div></div><div><h3>Conclusion</h3><div>Limited HL affected more than80% of patients with type 2 diabetes living in a socially deprived area of Greater Paris and remained independently associated with lower medication-purpose knowledge. These findings support routine assessment of HL and HL-sensitive educational interventions, with health mediators (patient navigators) representing a valuable complementary resource.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100327"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148730531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between therapeutic inertia and future hypoglycemia among patients with type 2 diabetes","authors":"Helen NC Chen ,&nbsp;Lap Pui Chung ,&nbsp;Yutong Chen ,&nbsp;Titus Schleyer ,&nbsp;Kai DeMeritt ,&nbsp;Ethan A. Halm ,&nbsp;Lisa S. Chow ,&nbsp;Lan Luo ,&nbsp;Julian Wolfson","doi":"10.1016/j.deman.2026.100305","DOIUrl":"10.1016/j.deman.2026.100305","url":null,"abstract":"<div><h3>Introduction</h3><div>Therapeutic inertia (TI), the failure to adjust therapy when HbA1c remains above- target, is a barrier to optimal glycemic control in type 2 diabetes (T2D). This study examined the association between TI and subsequent-year hypoglycemia visit, and whether continuous glucose monitoring (CGM) modifies this relationship.</div></div><div><h3>Methods</h3><div>We analyzed electronic health records (2017–2023) from two Midwest US healthcare systems, including adults with T2D, at least one above-target HbA1c (&gt;7% for ages 18–64; &gt;8% for ages ≥65), and glucose-lowering prescriptions. TI was calculated annually as the percentage of above-target HbA1c results without prescription changes within 30 days. We fitted logistic regression models to examine whether high TI (&gt;50%) was associated with subsequent-year hypoglycemia visits. An interaction term tested whether this association differed between those who used vs. did not use CGM.</div></div><div><h3>Results</h3><div>Among 65,983 participants (mean age 56, 51% male, 75% White), mean HbA1c at last follow-up was 8.1% (ages 18–64) and 8.0% (ages ≥ 65). High TI was associated with 74% increased odds of hypoglycemia visit (OR = 1.74; 95% CI: 1.61–1.88; <em>p</em> &lt; 0.001). Insulin users had threefold higher odds (OR = 2.95; <em>p</em> &lt; 0.001). Medicare beneficiaries had 47% higher odds than Medicaid beneficiaries. Adults aged 18–44 years had more hypoglycemia visits compared to other age groups. Low CGM use (7%) limited the interpretation of interaction effects (95% CI: 0.47–1.1, <em>p</em> = 0.12).</div></div><div><h3>Conclusions</h3><div>In this cohort, high TI predicted hypoglycemia-visit. Further research is needed to understand TI drivers and how to balance improving glycemic control without increasing the risk of hypoglycemia.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100305"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in age-adjusted mortality among older U.S. adults with co-morbid diabetes and hypertensive diseases: A multiple cause of death analysis, 1999–2023","authors":"Meer Murtaza ,&nbsp;Hafsa Shahid ,&nbsp;Muhammad Bilal Khanzada ,&nbsp;Inshrah Nawaz ,&nbsp;Ayeza Nawaz ,&nbsp;Iffat Ambreen Magsi ,&nbsp;Fentahun Bikale Kebede ,&nbsp;Aniqua Aftab ,&nbsp;Muhammad Seerat Ali ,&nbsp;Hassan Qadir ,&nbsp;Mehtab Ali","doi":"10.1016/j.deman.2026.100304","DOIUrl":"10.1016/j.deman.2026.100304","url":null,"abstract":"<div><h3>Introduction</h3><div>Diabetes mellitus (DM) increases the risk of Hypertension (HTN) through mechanisms such as vascular dysfunction, increased arterial stiffness, and diabetic kidney disease. Both DM and HTN often occur together due to shared risk factors and are common in the United States. We analyzed trends in DM and HTN-related mortality in the U.S. from 1999 to 2023, focusing on sex, racial, and regional differences, as well as specific age groups.</div></div><div><h3>Methods</h3><div>The CDC WONDER database was used to extract mortality data among adults (≥ 65 years old) in the US with concomitant DM and HTN from 1999 to 2023, expressed per 100,000 persons. Age-Adjusted Mortality Rates (AAMRs) were stratified by year, gender, race, age groups, and geographic distribution. The change in AAMRs was calculated as Annual Percentage Change (APC) with 95% Confidence Intervals (CIs).</div></div><div><h3>Results</h3><div>A total of 2132,393 deaths related to the co-morbidity of DM and HTN were recorded between 1999 and 2023. The AAMRs increased from 59.89 to 264.18 deaths per 100,000 population during this period, representing a 4.4-fold increase relative to the 1999 rate. A peak in mortality occurred during 2018-2021, with the AAMR reaching 302.62 in 2021 and an APC of 15.33 (95 % CI: 9.13 to 21.87; p = 0.00007). Men consistently had higher AAMRs than women (325.39 vs. 216.94 in 2023). Among racial and ethnic groups, NH Black or African American individuals had the highest average AAMR, followed by NH American Indian or Alaska Native, Hispanic or Latino, NH Asian or Pacific Islander, and NH White populations. Mortality rates increased with age, with those aged 85+ showing the highest averages, followed by the 75–84 and 65–74 age groups. From 1999 to 2023, the South had the highest average AAMR, followed by the West, Midwest, and Northeast. Rural areas exhibited significantly higher average AAMR (198.27 vs. 178.7) than urban areas from 1999 to 2020. The location of death varied: 37.56 % occurred in medical facilities, 30.45 % at the decedent’s home, 3.41 % in hospices, 24.62 % in nursing homes, and 3.96 % in other or unknown places. The highest AAMRs were observed in Mississippi (324.78), the District of Columbia (323.76), and Oklahoma (302.29), while the lowest were in Massachusetts (98.54), Connecticut (112.04), and Utah (113.23).</div></div><div><h3>Conclusion</h3><div>DM and HTN-related mortality have risen significantly over time in the United States, with a peak between 2018 and 2021. Our study shows a 4.4-fold increase in DM and HTN-related deaths in the U.S. from 1999 to 2023. The highest rates were observed in men aged 85+ from rural areas of the NH Black community in the Southern region. This underscores the need for enhanced public health surveillance, better healthcare, and targeted interventions for these groups to reduce disparities.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100304"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of chronic kidney disease and associated risk factors in patients with Type 2 Diabetes Mellitus in Basrah, Iraq: A cross-sectional study","authors":"Haider Ayad Alidrisi,&nbsp;Khulood Abed Reman,&nbsp;Emad Sakran Alhubaish,&nbsp;Ibrahim Hani Hussein,&nbsp;Hussein Ali Nwayyir,&nbsp;Ibrahim Abbood Zaboon,&nbsp;Musaab Ali Ashkar,&nbsp;Ali Hussain Alhamza,&nbsp;Abbas Ali Mansour","doi":"10.1016/j.deman.2026.100301","DOIUrl":"10.1016/j.deman.2026.100301","url":null,"abstract":"<div><h3>Aims</h3><div>Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is underdiagnosed. We aimed to evaluate the prevalence of undiagnosed CKD in patients with T2DM and identify factors associated with increased prevalence of CKD.</div></div><div><h3>Methods</h3><div>This cross-sectional study included patients with T2DM presenting for their visit to two centers in Basrah, Southern Iraq. CKD was diagnosed based on the measurement of estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR). The association of the patients’ demographic and biochemical characteristics with CKD was analyzed using logistic regression analysis.</div></div><div><h3>Results</h3><div>Among 1779 patients (mean age 55.0 ± 11.5 years, 39.0% male, mean T2DM duration 8.9 ± 6.9years), CKD was diagnosed in 887 (49.9%) patients. Specifically, 13.4% had eGFR &lt;60 mL/min/1.73 m²and 45.4% had UACR ≥30 mg/g. Independent predictors of CKD included increasing age (OR 1.03,95% CI 1.02–1.04), longer T2DM duration (OR 1.03, 95% CI 1.01–1.04), elevated HbA1c (OR 1.1, 95% CI1.09–1.19), higher total cholesterol (OR 1.008, 95% CI 1.003–1.01), uncontrolled hypertension (OR 1.4,95% CI 1.03–2.10), and lower HDL cholesterol (OR 0.9, 95% CI 0.9–0.99).</div></div><div><h3>Conclusions</h3><div>CKD was highly prevalent, affecting almost half of the patients with T2DM. Our findings highlighted the multiple risk factors associated with CKD and emphasized the importance of active CKD screening and comprehensive management strategies.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100301"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of SGLT2 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus: An effectiveness and safety analysis","authors":"Ricardo E T Navarrete ,&nbsp;Joao Fernandes ,&nbsp;Isabel Fonseca ,&nbsp;José Luis Silvano ,&nbsp;La Salete Martins ,&nbsp;Joao Roberto Sa","doi":"10.1016/j.deman.2026.100302","DOIUrl":"10.1016/j.deman.2026.100302","url":null,"abstract":"<div><h3>Background</h3><div>Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are key cardiorenal agents, yet their safety and efficacy in kidney transplant recipients (KTRs) with post-transplant diabetes mellitus (PTDM) remain insufficiently characterized.</div></div><div><h3>Objective</h3><div>To evaluate the renal safety, tolerability, and cardiometabolic profile associated with SGLT2 inhibitor use in this population.</div></div><div><h3>Methods</h3><div>This single-center retrospective cohort screened 183 KTRs prescribed GLP-1 receptor agonists and/or SGLT2i (August 2013–April 2024). After applying prespecified exclusion criteria, 65 kidney transplant recipients with PTDM receiving SGLT2i for &gt;3 months were included (mean treatment duration 2.56 ± 1.37 years). Primary outcomes were renal safety (annualized eGFR slope and uPCR/uACR). Secondary outcomes included cardiometabolic/hemodynamic measures and adverse events.</div></div><div><h3>Results</h3><div>Allograft function was stable, with an annualized eGFR slope of +1.35 mL/min/1.73 m²/year (95% CI: –0.49 to +3.19; p = 0.148). Proteinuria markers (uPCR, uACR) showed no significant increase. Serum urea rose (70.00 ± 25.80 to 75.30 ± 33.86 mg/dL, p = 0.003), while serum creatinine and cystatin C were unchanged. Body weight decreased by 3.02 kg (p = 0.001) and BMI by 1.24 kg/m² (p &lt; 0.001). Systolic and diastolic blood pressure were lower by 7.0 and 4.9 mmHg, respectively (both p &lt; 0.001). Reductions were observed in total cholesterol (172.60 ± 33.60 to 158.90 ± 37.70 mg/dL, p = 0.001) and LDL-cholesterol (87.60 ± 36.20 to 75.80 ± 33.60 mg/dL, p = 0.001). Serum uric acid decreased from 6.56 ± 1.56 to 6.24 ± 1.65 mg/dL (p = 0.021). Electrolytes were stable. Urinary tract infections occurred in 15.4% (predominantly asymptomatic). No cases of euglycemic diabetic ketoacidosis, allograft rejection, or genital infections were observed.</div></div><div><h3>Conclusions</h3><div>In KTRs with PTDM, intermediate-term SGLT2i therapy was associated with preserved allograft function, cardiometabolic benefits, and a favorable safety profile. These real-world data describe a clinical profile supporting further investigation and provide rationale for prospective trials.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100302"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long work hours, suboptimal diabetes management, and differences by sex and race/ethnicity, NHANES (2011-2018)","authors":"Tailisha Gonzalez ,&nbsp;Margrethe Horlyck-Romanovsky ,&nbsp;Terry T-K Huang ,&nbsp;Sandra E. Echeverria","doi":"10.1016/j.deman.2026.100316","DOIUrl":"10.1016/j.deman.2026.100316","url":null,"abstract":"<div><div>In the United States (US), occupational segregation by sex and race/ethnicity can contribute to health disparities. Although work schedule characteristics have been previously linked to elevated cardiovascular risk, little is known about the effects on chronic disease management in women and minoritized workers. We examined the association between work hours and diabetes management among US workers, testing for differences by sex and race/ethnicity. We utilized 2011–2018 National Health and Nutrition Examination Survey (NHANES) data on working adults (age ≥20 years) with diagnosed diabetes (<em>n</em> = 1041). Suboptimal diabetes management was defined as HbA1c ≥7%. Work hours were categorized per WHO guidelines (&lt;35hrs/week, 35–40, 41–54, ≥55). We conducted additional analyses with the US-standard (&lt;35hrs/week, 35–40,&gt;40). Log binomial regression models generated crude and adjusted prevalence ratios (aPR). We tested for interaction by sex and race/ethnicity. Significance levels were set at <em>p</em> &lt; 0.05. More than half (54.6%) of US workers with diabetes had HbA1c ≥7% (<em>p</em> &lt; 0.001). Pooled analyses showed no significant associations between work hours and diabetes management. In stratified models with WHO categorized work hours, working ≥55 h/week increased the prevalence of suboptimal diabetes management among women (aPR:1.85; 95%CI: 1.28–2.67), Latino (aPR: 1.37; 95%CI: 1.03–1.82), and White (aPR: 1.50; 95%CI: 1.04–2.15) workers compared to similar groups working 35–40 h/week. The analysis with US-standard hours masked differences for racial/ethnic groups, but not women and men. In both analyses, &lt;35 h/week was protective for men only. This study highlights the urgent need to examine how and for whom work conditions contribute to health inequities.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100316"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147802511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study-detected albuminuria among US adults with hypertension, diabetes, or both without self-reported kidney disease: A contemporary NHANES cross-sectional study","authors":"Hongyu Li,&nbsp;Xianlan Duan,&nbsp;Lixia Jin,&nbsp;Zhaoxiang Liu,&nbsp;Jianzhong Xiao,&nbsp;Wenhui Zhao","doi":"10.1016/j.deman.2026.100326","DOIUrl":"10.1016/j.deman.2026.100326","url":null,"abstract":"<div><div>Chronic kidney disease awareness remains low, and urine albumin testing may be underused even among adults with established cardiometabolic risk. We evaluated the contemporary burden and distribution of albuminuria among United States adults with diabetes, hypertension, or both who did not report a history of kidney disease. This cross-sectional study used nationally representative data from the National Health and Nutrition Examination Survey, including the 2017–March 2020 prepandemic cycle and the August 2021–August 2023 cycle. The analytic cohort included nonpregnant adults aged 20 years or older with diabetes, hypertension, or both, after excluding those with a self-reported history of kidney disease or dialysis. Study-detected albuminuria was defined as a urinary albumin-to-creatinine ratio of at least 30 mg/g measured during the NHANES examination among participants without a self-reported history of kidney disease or dialysis; severe albuminuria was defined as a ratio of at least 300 mg/g. Survey-weighted prevalence estimates were calculated, and survey-weighted Poisson regression was used to estimate adjusted prevalence ratios. Among 6671 high-risk adults without a self-reported history of kidney disease, 17.4% (95% CI, 16.4%–18.4%) had albuminuria and 2.7% had severe albuminuria. Albuminuria prevalence was 11.7% among adults with hypertension alone, 19.4% among those with diabetes alone, and 32.6% (95% CI, 30.0%–35.2%) among those with both hypertension and diabetes. Among participants with preserved estimated glomerular filtration rate of at least 60 mL/min/1.73 m², albuminuria prevalence was 15.3% overall and reached 30.7% (95% CI, 27.7%–33.7%) among adults with both conditions. In the primary multiply imputed analysis, diabetes alone and both hypertension and diabetes were associated with higher albuminuria prevalence than hypertension alone, with adjusted prevalence ratios of 1.60 (95% CI, 1.34–1.93) and 2.38 (95% CI, 2.07–2.74), respectively. Among United States adults with diabetes, hypertension, or both who did not report a history of kidney disease, albuminuria was common, particularly among those with both conditions. These findings provide a contemporary estimate of study-detected albuminuria burden among adults with hypertension, diabetes, or both. When considered alongside prior evidence of underuse of urine albumin testing, the substantial burden observed in these high-risk groups highlights an opportunity to strengthen kidney-risk assessment, while abnormal UACR findings require confirmation before persistent albuminuria or CKD is established.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100326"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148634437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The impact of oral health on fasting blood sugar levels in diabetic individuals: insights from the PERSIAN Guilan cohort study” [Diabetes Epidemiology and Management 19-20 (2025) 100268]","authors":"Amir Valaei-Barhagh,&nbsp;Mohammad Samami,&nbsp;Farahnaz Joukar,&nbsp;Soheil Hassanipour,&nbsp;Saqar Zaker,&nbsp;Maryam Rabiei,&nbsp;Mohammad Reza Naghipour,&nbsp;Fariborz Mansour-Ghanaei","doi":"10.1016/j.deman.2026.100333","DOIUrl":"10.1016/j.deman.2026.100333","url":null,"abstract":"","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100333"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148934362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcomes of patients with chronic kidney disease hospitalized with diabetic ketoacidosis","authors":"Ziv Ribak ,&nbsp;Elizaveta Milver ,&nbsp;Ilan Rahmani Zvi Ran ,&nbsp;Alan Jotkowitz ,&nbsp;Noa Sadigurschi ,&nbsp;Leonid Barski","doi":"10.1016/j.deman.2026.100321","DOIUrl":"10.1016/j.deman.2026.100321","url":null,"abstract":"<div><h3>Background</h3><div>Managing diabetic ketoacidosis (DKA) in patients with chronic kidney disease (CKD) is complex due to altered glucose metabolism, insulin sensitivity, and medication clearance. Current guidelines primarily address patients with normal or mildly impaired renal function, leaving a gap for those with advanced CKD. This study evaluated outcomes and management of DKA in patients with varying degrees of CKD.</div></div><div><h3>Methods</h3><div>In this retrospective study (2005–2023), adults hospitalized with DKA were stratified by baseline eGFR: ≥60, 30–59, and &lt;30 mL/min/1.73m². Primary outcome was length of hospital stay; secondary outcomes included one-year mortality, in-hospital and 30-day mortality and DKA recurrence.</div></div><div><h3>Results</h3><div>Of 318 patients, 277 had eGFR ≥60, 24 had 30-59, and 17 had &lt;30. Patients with advanced CKD (eGFR &lt;30) exhibited significantly prolonged median LOS (9 vs. 4 days; P=0.002) and higher 1-year mortality (52.9% vs. 10.1%; P&lt;0.001). In multivariate analysis, advanced CKD remained a robust independent predictor of a 2.3-fold increase in LOS (IRR 2.29, P=0.002), a 3.5-fold increased risk of 1-year mortality (HR 3.57, P=0.002), and a more than 3-fold higher risk of DKA recurrence (SHR 3.38, P=0.007). These findings were further validated in the propensity-matched cohort. Notably, higher rates of fluid administration were independently associated with shorter LOS (P=0.012) across all groups.</div></div><div><h3>Conclusion</h3><div>Advanced CKD is a robust independent risk factor for mortality, recurrence, and prolonged hospitalization in DKA patients. Initial aggressive fluid resuscitation was not associated with adverse clinical outcomes, suggesting its safety in this high-risk population.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100321"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}